We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $606M
This Fund
S&P 500
This Quarter Est. Return
+32.72%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$606M
AUM Growth
+$288M
Cap. Flow
+$198M
Cap. Flow %
32.7%
Top 10 Hldgs %
65.14%
Holding
138
New
23
Increased
43
Reduced
23
Closed
42

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$118M
2
TNGX icon
Tango Therapeutics
TNGX
+$67.4M
3
RVMD icon
Revolution Medicines
RVMD
+$23.6M
4
PHVS icon
Pharvaris
PHVS
+$18.2M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.1M

Top Sells

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$7.49M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.63M
3
PCVX icon
Vaxcyte
PCVX
+$4.27M
4
SLNO
Soleno Therapeutics
SLNO
+$3.88M
5
KALV
KalVista Pharmaceuticals
KALV
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NERV icon
26
Minerva Neurosciences
NERV
$162M
$5.56M 0.92%
1,001,373
+752,897
+303% +$4.08M
EDIT icon
27
Editas Medicine
EDIT
$396M
$4.31M 0.71%
+1,330,500
New +$3.89M
CTMX icon
28
CytomX Therapeutics
CTMX
$588M
$4.07M 0.67%
1,085,398
+714,000
+192% +$2.73M
EPRX
29
Eupraxia Pharmaceuticals
EPRX
$529M
$4.04M 0.67%
610,785
+177,270
+41% +$1.22M
STRO icon
30
Sutro Biopharma
STRO
$265M
$3.79M 0.63%
+159,118
New +$4.96M
RLAY icon
31
Relay Therapeutics
RLAY
$3.83B
$3.33M 0.55%
178,222
-79,516
-31% -$1.15M
CLDX icon
32
Celldex Therapeutics
CLDX
$2.44B
$3.22M 0.53%
86,664
+57,364
+196% +$1.85M
ASND icon
33
Ascendis Pharma A/S
ASND
$14.8B
$3.17M 0.52%
11,869
-310
-3% -$72.4K
SGMT icon
34
Sagimet Biosciences
SGMT
$574M
$3.12M 0.51%
+403,545
New +$2.74M
ZLAB icon
35
Zai Lab
ZLAB
$2.8B
$2.92M 0.48%
136,016
+58,158
+75% +$1.15M
SABS icon
36
SAB Biotherapeutics
SABS
$299M
$2.87M 0.47%
736,077
+636,077
+636% +$2.37M
MDGL icon
37
Madrigal Pharmaceuticals
MDGL
$11.9B
$2.67M 0.44%
4,973
+1,580
+47% +$809K
PRAX icon
38
Praxis Precision Medicines
PRAX
$7.84B
$2.52M 0.42%
+7,540
New +$2.39M
RLMD icon
39
Relmada Therapeutics
RLMD
$409M
$2.41M 0.4%
+348,265
New +$2.43M
AGIO icon
40
Agios Pharmaceuticals
AGIO
$1.95B
$2.11M 0.35%
56,900
-152,647
-73% -$4.63M
XENE icon
41
Xenon Pharmaceuticals
XENE
$3.58B
$2.08M 0.34%
+33,300
New +$1.85M
SVRA icon
42
Savara
SVRA
$1.03B
$1.9M 0.31%
309,103
+13,415
+5% +$72K
CCCC icon
43
C4 Therapeutics
CCCC
$367M
$1.78M 0.29%
381,169
+324,093
+568% +$1.11M
PCVX icon
44
Vaxcyte
PCVX
$8.36B
$1.78M 0.29%
29,800
-78,650
-73% -$4.27M
CELC icon
45
Celcuity
CELC
$3.89B
$1.7M 0.28%
16,252
+10,252
+171% +$1.18M
SNDX icon
46
Syndax Pharmaceuticals
SNDX
$1.63B
$1.65M 0.27%
+77,930
New +$1.62M
ZNTL icon
47
Zentalis Pharmaceuticals
ZNTL
$256M
$1.45M 0.24%
317,600
+207,600
+189% +$829K
GPCR icon
48
Structure Therapeutics
GPCR
$2.56B
$1.44M 0.24%
26,800
+17,800
+198% +$788K
LONA
49
LeonaBio Inc
LONA
$30.6M
$1.42M 0.23%
154,153
-10,523
-6% -$97.9K
IDYA icon
50
IDEAYA Biosciences
IDYA
$3.54B
$1.41M 0.23%
37,865
-48,418
-56% -$1.48M
1
2
3 4 5

Similar funds

NPPM
North Point Portfolio Managers Orange Village, Ohio $606M AUM 20.84% 1-Year Est. Return
SCM
SKBA Capital Management San Francisco, California $606M AUM 13.33% 1-Year Est. Return
BFC
Banc Funds Company Chicago, Illinois $605M AUM 26% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
CM
Conifer Management New York $607M AUM 29.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
MCM
Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return

Seven Fleet Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Seven Fleet Capital Management held 138 positions worth $606M, up 90% from $318M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Seven Fleet Capital Management deployed $198M of net new capital in Q2 2026, opening 23 new positions and adding to 43 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 56% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $4.63M trimmed.

  • Seven Fleet Capital Management's largest Q2 2026 buy was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.
  • Seven Fleet Capital Management added most to CG Oncology in Q2 2026, an estimated $118M increase.
  • Seven Fleet Capital Management's biggest Q2 2026 reduction was Agios Pharmaceuticals, cutting an estimated $4.63M.
  • Seven Fleet Capital Management fully exited Tyra Biosciences in Q2 2026, selling an estimated $7.49M.
  • Seven Fleet Capital Management's ten largest holdings make up 65% of its $606M portfolio in Q2 2026.
  • Seven Fleet Capital Management opened 23 new positions and closed 42 in Q2 2026.
  • Seven Fleet Capital Management's portfolio value rose 90% quarter-over-quarter to $606M.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.